New England Journal of Medicine· 2016Q1· Clinical trial

Belatacept and Long-Term Outcomes in Kidney Transplantation

Flavio Vincenti, Lionel Rostaing, J.M. Boria Grinyo, Kim Rice et al.

762citations
Q1SCImago
2016year

Short summary

After 7 years, kidney transplant recipients on belatacept-based immunosuppression showed a 43% reduction in the risk of death or graft loss compared to those on cyclosporine, with significantly improved kidney function.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Transplantation

TransplantationMedicine